Aquestive – $74 Million IPO

New York – September 12, 2018 – Cooley advised the underwriters on Aquestive Therapeutics' $73.9 million initial public offering of 4,925,727 shares of common stock, which includes the partial exercise of the underwriters’ option to purchase additional shares. Partners Daniel Goldberg, Ryan Sansom and Div Gupta led the Cooley team advising the underwriters.

BMO Capital Markets and RBC Capital Markets acted as the joint book-running managers for the offering. Wedbush PacGrow and JMP Securities acted as co-lead managers for the offering.

Aquestive Therapeutics, which now trades on the Nasdaq Global Market as “AQST,” is a specialty pharmacy company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.


Related Contacts
Daniel I. Goldberg Partner, New York
Ryan Sansom Partner, Boston
Div Gupta Partner, New York
Dayne Brown Associate, New York
Danielle Gershowitz Associate, New York
Lily Colahan Associate, Boston
Adam Alperowicz Associate, New York
Related Practices & Industries

Capital Markets Public Companies Life Sciences